PharmAla Partners with Clariti Strategic Advisors™ PharmAla signs long-term partnership with Clariti Strategic Partners as its investment banking and advisory firm

PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...

Optimi Health Granted Natural Health Product Site Licence By Health Canada VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...

Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer...

PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics VANCOUVER, British Columbia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce that it has signed on to act as exclusive supplier of...